原始出处Hart RG, Pearce LA, Aguilar MI. (2007). Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine, 146(12), 857-867. doi.org/10.7326/0003-4819-146-12-20070619…;Aguilar MI, Hart R. (2005). Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, (3), CD001927. doi.org/10.1002/14651858.CD001927.pub2;Ruff CT, Giugliano RP, Braunwald E, et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 383(9921), 955-962. doi.org/10.1016/S0140-6736(13)62343-0;Connolly SJ, Eikelboom J, Joyner C, et al. (2011). Apixaban in patients with atrial fibrillation. New England Journal of Medicine, 364(9), 806-817. doi.org/10.1056/NEJMoa1007432;Mant J, Hobbs FD, Fletcher K, et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, 370(9586), 493-503. doi.org/10.1016/S0140-6736(07)61233-1;Ma CS, Wu SL, Liu SW, Han YL, Chinese Society of Cardiology, et al. (2024). Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation. Journal of Geriatric Cardiology, 21(3), 251-314(中华医学会心血管病学分会等 2023 年《心房颤动诊断和治疗中国指南》的英文版). doi.org/10.26599/1671-5411.2024.03.009;Joglar JA, Chung MK, Armbruster AL, et al. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation, 149(1), e1-e156. doi.org/10.1161/CIR.0000000000001193;Du X, Guo L, Xia S, et al. (2021). Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. Heart. doi.org/10.1136/heartjnl-2020-317915;Shi S, Tang Y, Zhao Q, et al. (2022). Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study. Lancet Regional Health – Western Pacific, 23, 100439. doi.org/10.1016/j.lanwpc.2022.100439;US Preventive Services Task Force (2022). Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA, 327(4), 360-367. doi.org/10.1001/jama.2021.23732;Svennberg E, Friberg L, Frykman V, et al. (2021). Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet, 398(10310), 1498-1506. doi.org/10.1016/S0140-6736(21)01637-8;Svendsen JH, Diederichsen SZ, Højberg S, et al. (2021). Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet, 398(10310), 1507-1516. doi.org/10.1016/S0140-6736(21)01698-6